calpurbatug

also known as TRL1068

Developed for: periprosthetic joint infection · chronic rhinosinusitis
Investigated by: Trellis Bioscience LLC · Biomedical Advanced Research and Development Authority · Gulfcoast Research Institute · National Institute of Allergy and Infectious Diseases (NIAID) · Phoenix Clinical Research · Sinai Hospital of Baltimore
+7 more
· The Methodist Hospital Research Institute · University of Alabama at Birmingham · University of California, Los Angeles · University of Florida · University of Southern California · University of Virginia · Wellcome Trust

2021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT07644195	Oct → Dec 2026 expected	—	Trellis Bioscience LLC	Not yet recruiting	No outcome recorded
Phase 1	NCT05355207	Jan 2024 → Jan 2025	chronic rhinosinusitis	Trellis Bioscience LLC	Unknown	No outcome recorded
Phase 1	NCT04763759	Feb 2021 → Mar 2024	periprosthetic joint infection	Trellis Bioscience LLC	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT06621251	Apr 2025 → Apr 2027 expected	periprosthetic joint infection	Trellis Bioscience LLC	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	calpurbatug	“TRL1068 (calpurbatug), a human monoclonal antibody” NCT06621251 ↗
Known as	TRL1068	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04763759 ↗ 3 NCT07644195 ↗ NCT06621251 ↗ NCT05355207 ↗
Modality	Monoclonal antibody	“TRL1068, a native human monoclonal antibody” PMID 39012102 ↗ Jul 2024
Route	Intravenous	“TRL1068 was administered via a single pre-surgical intravenous infusion in three sequentially ascending dose groups (6, 15, and 30 mg/kg).” PMID 39012102 ↗ Jul 2024